Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“ PMX ”), is pleased to announce the closing of the second and final tranche of …
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


